<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23964" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Kyrle Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rice</surname>
            <given-names>Ashley S.</given-names>
          </name>
          <aff>CUSOM/Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zedek</surname>
            <given-names>Daniel</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashley Rice declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Zedek declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23964.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Kyrle disease is a rare papular eruption on the lower extremities of patients with chronic systemic diseases, most commonly renal failure and diabetes mellitus. Treatment is often dependent on the management of the underlying systemic disease. This activity reviews the evaluation and management of Kyrle disease and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for developing Kyrle disease.</p></list-item><list-item><p>Outline the typical presentation and common exam findings associated with Kyrle disease.</p></list-item><list-item><p>Summarize the management considerations for patients with Kyrle disease.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by Kyrle disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23964&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23964">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23964.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kyrle disease is a rare skin condition classified as a subtype of&#x000a0;acquired perforating dermatosis, along with reactive perforating collagenosis, elastosis perforans serpinginosa, and perforating folliculitis.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref>&#x000a0;It was first described in 1916 by Austrian pathologist and dermatologist Josef Kyrle in a diabetic woman with generalized hyperkeratotic papules and was originally coined&#x000a0;"hyperkeratosis follicularis et parafollicularis in cutem penetrams."<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r2">[2]</xref>&#x000a0;Due to significant clinical overlap, follicular and non-follicular morphology, and variations in histology with differing disease stages, acquired&#x000a0;perforating dermatosis&#x000a0;was proposed&#x000a0;as an umbrella term for all adult-onset perforating disorders. However, there is controversy in the literature as to the classification of Kyrle disease. While&#x000a0;some&#x000a0;authors use Kyrle disease interchangeably with acquired perforating dermatosis, others define it as a variant of prurigo nodularis that represents end-stage excoriated folliculitis.<xref ref-type="bibr" rid="article-23964.r3">[3]</xref></p>
        <p>Kyrle disease most commonly manifests as multiple, discrete, eruptive papules with a central keratotic plug on the lower extremities. On histopathology, there is a characteristic&#x000a0;transepidermal elimination of abnormal keratin.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r3">[3]</xref>&#x000a0;The exact etiology of Kyrle disease has not been elucidated. The majority of case reports suggest it occurs secondary&#x000a0;to chronic systemic diseases, most commonly renal failure (stages 4 and 5) and diabetes mellitus. Meanwhile, evidence&#x000a0;of Kyrle disease as a primary perforating disorder has been seen in small case reports that show&#x000a0;a genetic predisposition. Treatment can be difficult and typically focuses on the management of underlying medical conditions. Keratolytic agents are also recommended as first-line therapy.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r3">[3]</xref></p>
      </sec>
      <sec id="article-23964.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of Kyrle disease is unknown. Many theories have been proposed in the literature including infectious, abnormal keratinization, defective differentiation of the epidermis and dermo-epidermal junction, elevated serum and tissue concentrations of fibronectin, uremia (renal failure), and hyperphosphatemia (diabetes mellitus).&#x000a0;The high incidence of systemic disease associated with the development of Kyrle disease suggests an underlying systemic disorder as the main etiology.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r3">[3]</xref></p>
        <p>Small case reports have shown a possible&#x000a0;genetic predisposition with discoveries of both autosomal dominant and autosomal recessive inheritance patterns. However, familial predisposition has not been extensively studied, and future studies are warranted to determine&#x000a0;genomic significance.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r3">[3]</xref></p>
      </sec>
      <sec id="article-23964.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Kyrle disease typically occurs during adulthood between the age of 30 and 50 years. There is a higher incidence in females with a female-to-male ratio of up to 6:1.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref></p>
        <p>Kyrle disease is most commonly associated with chronic renal disease and diabetes mellitus, particularly in those with associated diabetic nephropathy. It is estimated that 10% of hemodialysis patients will eventually develop Kyrle disease.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r4">[4]</xref>&#x000a0;In rare cases, it has been seen in tuberculosis, pulmonary aspergillosis, scabies, atopic dermatitis, AIDS, neurodermatitis, malignancy, hepatic disorders, congestive heart failure, and endocrinological disorders.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref></p>
      </sec>
      <sec id="article-23964.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In the setting of systemic disease, it is postulated that various metabolic derangements underlie the pathophysiology of Kyrle disease. The fact that Kyrle disease also occurs in non-diabetic renal diseases suggests uremia, rather than hyperglycemia, as the causative factor in diabetic and renal failure patients.<xref ref-type="bibr" rid="article-23964.r3">[3]</xref>&#x000a0;In patients with diabetic nephropathy, Joseph et al. <xref ref-type="bibr" rid="article-23964.r4">[4]</xref>&#x000a0;found that the only consistent abnormality was hyperphosphatemia, suggesting a role in the pathogenesis. It is theorized that excess urea and/or phosphate is deposited in the dermis with subsequent extrusion of the material through epidermal follicular openings and the formation of perforating canals.<xref ref-type="bibr" rid="article-23964.r4">[4]</xref></p>
        <p>In addition, serum and immunohistochemical studies have shown an increase in fibronectin levels and deposition, which may play a role in inciting epithelial migration and proliferation, leading to perforation.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r5">[5]</xref>&#x000a0;Others have suggested that advanced glycosylation end products and oxidized low-density lipoproteins lead to abnormal keratinization, defective differentiation of the epidermis and dermo-epidermal junction, and vasculopathy. This causes a cutaneous response in the form of transdermal elimination.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r6">[6]</xref>&#x000a0;Lastly, a single case report proposed the role of anaerobic bacteria in the pathogenesis of Kyrle disease based on the regression of skin lesions with clindamycin.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r7">[7]</xref></p>
      </sec>
      <sec id="article-23964.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Kyrle disease is characterized by transdermal elimination of keratotic material with no collagen or elastic fibers. This differentiates Kyrle disease from other acquired perforating disorders that exhibit transdermal elimination of collagen and elastic fibers. These include reactive perforating collagenosis, elastosis perforans serpinginosa, and perforating folliculitis. In addition, there is an overlying keratotic plug in an atrophic-appearing epidermis. A foreign body granulomatous reaction composed of dermal histiocytic and lymphocytic infiltrates may be present. Orthokeratosis, parakeratosis, and abnormal keratinization may also be observed.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref></p>
      </sec>
      <sec id="article-23964.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Kyrle disease typically presents as hyperkeratotic papules and nodules with a central keratotic plug. Skin lesions occur most commonly on the lower extremities, especially the calf, tibial region, and posterior aspect. It may also affect the arms and head and neck regions. Rarely, there is the involvement of the palms and soles.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref>&#x000a0;Koebnerization, in which skin lesions form at sites of injury, has also been reported.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r8">[8]</xref></p>
      </sec>
      <sec id="article-23964.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Kyrle disease is diagnosed based on characteristic clinical and histopathologic findings. A parakeratotic plug is present in epidermal depression. It may involve hair follicles. Basophilic debris is present in the plug. Blood glucose level is checked to evaluate underlying diabetes mellitus. Liver and renal function tests are done for underlying liver and kidney disease. Patients should have a close clinical follow-up of any underlying systemic diseases by their primary care provider and other corresponding specialty providers.</p>
      </sec>
      <sec id="article-23964.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>To date, there are no well-designed randomized control trials studying treatment therapies for Kyrle disease. Treatment recommendations are currently based&#x000a0;on&#x000a0;anecdotal reports or small case series. Keratolytics such as salicylic acid or urea are considered&#x000a0;first-line therapy. Emollients and oral antihistamines have been used to relieve pruritus. Electrocautery, cryotherapy, CO2 laser, topical retinoids, isotretinoin, and psoralen plus ultraviolet A radiation are alternative therapies. Oral clindamycin 300 mg three 3 a day for one month has also shown beneficial results.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref>&#x000a0;Discontinuation of these therapies often results in recurrence of skin lesions,<xref ref-type="bibr" rid="article-23964.r1">[1]</xref><xref ref-type="bibr" rid="article-23964.r9">[9]</xref>&#x000a0;although there have been reports of complete regression after renal transplantation in dialysis patients.<xref ref-type="bibr" rid="article-23964.r10">[10]</xref>&#x000a0;Surgical excision is reserved for severe, refractory cases.<xref ref-type="bibr" rid="article-23964.r1">[1]</xref></p>
      </sec>
      <sec id="article-23964.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Kyrle disease must be differentiated from other disorders that cause papular or nodular eruptions with hyperkeratotic central plugs. These include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prurigo nodularis&#x000a0;(some authors argue Kyrle disease is a variant of prurigo nodularis)<xref ref-type="bibr" rid="article-23964.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Multiple keratoacanthomas&#x000a0;(can also mimic Kyrle disease histologically)</p>
          </list-item>
          <list-item>
            <p>Excoriated lesions (prurigo simplex)</p>
          </list-item>
          <list-item>
            <p>Folliculitis</p>
          </list-item>
          <list-item>
            <p>Arthropod hypersensitivity reaction</p>
          </list-item>
          <list-item>
            <p>Perforation of exogenous or endogenous foreign material</p>
          </list-item>
          <list-item>
            <p>Dermatofibromas</p>
          </list-item>
        </list>
        <p>If koebnerization occurs, more linearly distributed lesions should be included in the differential. These include&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
          <list-item>
            <p>Verrucae</p>
          </list-item>
        </list>
        <p>Diagnosis can be difficult as patients with acquired perforating disorders often have co-existing folliculitis and prurigo nodularis.<xref ref-type="bibr" rid="article-23964.r3">[3]</xref>&#x000a0;In addition, histology may represent various lesions at different stages. Patients who have a history of diabetes mellitus with concomitant renal disease or those on hemodialysis are more likely to have an acquired perforating disease.</p>
      </sec>
      <sec id="article-23964.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of Kyrle diseases depends upon the severity of underlying systemic diseases like diabetes mellitus, chronic kidney disease, and liver disease. The morbidity of Kyrle disease is due to the appearance of lesions and intense itching. Morbidity and mortality are directly associated with the underlying systemic diseases.</p>
      </sec>
      <sec id="article-23964.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Kyrle disease is limited to the skin and there are no systemic complications, instead, it is a manifestation of other uncontrolled systemic disorders.</p>
      </sec>
      <sec id="article-23964.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients must be educated about the nature of the disease and also to control the underlying systemic disease. Diabetic patients are asked to strictly control their blood sugar levels. Patients with renal disease should get proper treatment for uremia, Kyrle disease usually disappears when uremia is treated. Similarly, liver disease and heart failure management should be optimized.</p>
      </sec>
      <sec id="article-23964.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Kyrle disease commonly presents in patients with significant comorbidities such as end-stage renal disease and diabetes mellitus. Thus, it is imperative that dermatologists have a high index of suspicion for renal failure and/or diabetes mellitus or potential worsening of these disorders in patients presenting with Kyrle disease. Dermatologists and dermatology nurses must work closely with primary care providers and other specialty providers, such as nephrologists or endocrinologists, to prevent a negative impact on patients&#x02019; quality of life. Future studies on the morbidity and mortality of Kyrle disease are still needed as the current literature is&#x000a0;based on small case series.<xref ref-type="bibr" rid="article-23964.r11">[11]</xref>(Level V)</p>
      </sec>
      <sec id="article-23964.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23964&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23964">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/kyrle-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23964">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23964/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23964">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23964.s16">
        <title>References</title>
        <ref id="article-23964.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nair</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jivani</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Diwan</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Kyrle's disease in a patient of diabetes mellitus and chronic renal failure on dialysis.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>284</fpage>
            <page-range>284-6</page-range>
            <pub-id pub-id-type="pmid">25949985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moss</surname>
                <given-names>HV</given-names>
              </name>
            </person-group>
            <article-title>Kyrle's disease.</article-title>
            <source>Cutis</source>
            <year>1979</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-6</page-range>
            <pub-id pub-id-type="pmid">154994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapini</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Herbert</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Drucker</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both collagen and elastic fibers.</article-title>
            <source>Arch Dermatol</source>
            <year>1989</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>8</issue>
            <fpage>1074</fpage>
            <page-range>1074-8</page-range>
            <pub-id pub-id-type="pmid">2757403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joseph</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Papali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pisharody</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Kyrle's disease : a cutaneous marker of renal disorder.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>1996</year>
            <season>Jul-Aug</season>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>222</fpage>
            <page-range>222-5</page-range>
            <pub-id pub-id-type="pmid">20948059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Truitt</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Taira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Somach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitha</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Fibronectin and the extracellular matrix in the perforating disorders of the skin.</article-title>
            <source>Am J Dermatopathol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>147</fpage>
            <page-range>147-54</page-range>
            <pub-id pub-id-type="pmid">9557783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detmar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruszczak</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Imcke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orfanos</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>[Kyrle disease in juvenile diabetes mellitus and chronic renal failure].</article-title>
            <source>Z Hautkr</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-61</page-range>
            <pub-id pub-id-type="pmid">2327137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kasiakou</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Peppas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapaskelis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Regression of skin lesions of Kyrle's disease with clindamycin: implications for an infectious component in the etiology of the disease.</article-title>
            <source>J Infect</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>412</fpage>
            <page-range>412-6</page-range>
            <pub-id pub-id-type="pmid">15907549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fulton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Kyrle's disease.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1987</year>
            <month>Jan</month>
            <volume>16</volume>
            <issue>1 Pt 1</issue>
            <fpage>117</fpage>
            <page-range>117-23</page-range>
            <pub-id pub-id-type="pmid">3805380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hood</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hardegen</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Zarate</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Nigra</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Kyrle's disease in patients with chronic renal failure.</article-title>
            <source>Arch Dermatol</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-8</page-range>
            <pub-id pub-id-type="pmid">7059223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saldanha</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gonick</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Marmelzat</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Repique</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Silicon-related syndrome in dialysis patients.</article-title>
            <source>Nephron</source>
            <year>1997</year>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">9380238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23964.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akoglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sungu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurtoglu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Metin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological features of 25 patients with acquired perforating dermatosis.</article-title>
            <source>Eur J Dermatol</source>
            <year>2013</year>
            <season>Nov-Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>864</fpage>
            <page-range>864-71</page-range>
            <pub-id pub-id-type="pmid">24446068</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
